Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

GRN163L is a potent and specific telomerase inhibitor and in clinical trials for cancer treatment. To identify the biomarker that might predict response to telomease based therapy, gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L) was performed. HCT116, Colo205, OVCAR5 cells were either vehicle treated or Imetelstat treated for 2 weeks and then total RNA was preppared, which was then used to analyze for gene expression using Illumina expression array.